Clinical Trials Logo

Angina Pectoris clinical trials

View clinical trials related to Angina Pectoris.

Filter by:

NCT ID: NCT03438500 Withdrawn - Clinical trials for Coronary Artery Disease

Cardiac Shock Wave Treatment in Patients With Reduced Coronary Flow Reserve

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to assess the feasibility of Cardiac Shock Wave Treatment in patients with anginal chest pain and evidence of abnormal myocardial perfusion under stress in the absence of significant stenoses of the epicardial coronary arteries.

NCT ID: NCT03425305 Active, not recruiting - Heart Failure Clinical Trials

Serum Uric Acid Levels and Onset of Cardiovascular Diseases: a CALIBER Study

Start date: January 1998
Phase: N/A
Study type: Observational

Serum uric acid level is a commonly measured biomarker. The association between serum uric acid level and the risk of developing cardiovascular diseases has been observed in some studies, while others showed controversial results. Estimation of this association may help to predict cardiovascular outcomes and may guide new treatment strategies. The hypothesis is that increased serum uric acid level is associated with a range of cardiovascular diseases.

NCT ID: NCT03409731 Completed - Clinical trials for Coronary Artery Disease

Absorb GT1 Japan PMS

Start date: December 13, 2016
Phase: N/A
Study type: Interventional

The purpose of the Surveillance is to know the frequency and status of adverse device effects and adverse events in order to assure the safety of the new medical device, and to collect efficacy and safety information for evaluating clinical use results.

NCT ID: NCT03401502 Completed - Angina Clinical Trials

A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency

Start date: June 7, 2018
Phase: N/A
Study type: Interventional

This is a double-blind, randomized, placebo-controlled, and parallel study. The study is comprised of three main phases: a single-blind placebo run-in qualifying phase lasting about 14 days, a double-blind treatment phase of 12 weeks, and a 2-week follow-up phase. Approximately 18 patients will be enrolled and randomly assigned to receive placebo or 1,000 mg of extended-release Ranolazine twice-daily for 12 weeks to reach 14 evaluable patients at the end of the study.

NCT ID: NCT03392948 Active, not recruiting - Clinical trials for Acute Myocardial Infarction

PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy

PERSEO
Start date: February 9, 2018
Phase:
Study type: Observational [Patient Registry]

Approximately 5 to 8% of patients undergoing percutaneous coronary interventions requires chronic anticoagulant therapy due to atrial fibrillation or other clinical entities. There are many possible different combinations of the antithrombotic therapy after stent implantation in these patients. Aim of this observational study is to evaluate the real world antithrombotic treatment in patients requiring anticoagulant therapy undergoing stent implantation and to compare the clinical outcome of patients treated with new oral anticoagulant drugs compared to warfarin. The study is prospective, performed in different Italian hospitals and aimed to enroll 1080 patients with a 1 year follow up

NCT ID: NCT03392415 Recruiting - Heart Failure Clinical Trials

The NOrdic-Baltic Randomized Registry Study for Evaluation of PCI in Chronic Total Coronary Occlusion

NOBLE-CTO
Start date: June 1, 2018
Phase: N/A
Study type: Interventional

Randomized registry for the study of CTO PCI as adjunction to optimal medical therapy.

NCT ID: NCT03389503 Completed - Clinical trials for Coronary Artery Disease

Comparison of Left and Right Transradial Approach for CAG and PCI

COMPARE-Rad
Start date: March 8, 2017
Phase: N/A
Study type: Interventional

This trial will compare the procedural success rate between right and left radial approach in patients undergoing coronary angiography and coronary intervention.

NCT ID: NCT03350737 Completed - Clinical trials for Chronic Stable Angina

Coronary Arteriogenetic Heparinized Exercise

CARHEXA
Start date: February 1, 2013
Phase: N/A
Study type: Interventional

This study evaluates the addition of heparin to a 2-week cycle of physical rehabilitation in the treatment of refractory angina. Half of the patients will undergo heparin-primed physical rehabilitation, while the other half will undergo only physical rehabilitation.

NCT ID: NCT03341663 Completed - Clinical trials for Stable Angina Pectoris

The Diagnostic Value of Acupoint Sensitization Based on Stable Angina Pectoris

Start date: December 6, 2017
Phase:
Study type: Observational

Investigators adopt cross-sectional study design to carry out the exemplary research in the aspects of disease diagnosis.This study is designed to confirm the hypothesis "acupoint sensitization is associated with a severity of angina pectoris, which may contribute to the diagnosis of stable angina pectoris". After the eligible participants recruited in group, the coronary artery lesions will be evaluated through coronary angiography and the Canadian Cardiovascular Society(CCS) angina pectoris classification will also be evaluated at the same time. The degree of acupoint sensitization will be tested by the electronic Von Frey instrument by one professional acupuncturist with total 12 acupoints, including Shenmen,Yinxi, Shaohao,Jiquan,Neiguan, Ximen, Quze, Shanzhong, Juque, Jueyinyu, Xinyu, Duyu. Analysis were conducted to explore relationships between the degree of acupoint sensitization, the degree of coronary artery stenosis and CCS angina pectoris classification. Diagnostic value will be further analyzed in the final step.

NCT ID: NCT03338309 Active, not recruiting - Stable Angina Clinical Trials

INsTantenous wavE-Free Ratio-guided PCI Versus Fractional Flow REserve-Guided PCI in rouTine Clinical Practice, Prospective, Multicenter Registry

INTERPRET
Start date: November 1, 2017
Phase:
Study type: Observational [Patient Registry]

The current study sought to evaluate the clinical relevance of iFR-guided strategy in real world clinical practice using unrestricted study population from stable angina to acute coronary syndrome including acute ST-segment elevation myocardial infarction. Previous abundant historical data of FFR-guided strategy will be also included as historical control to validate the iFR-guided strategy.